Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Review and Update on the Use of Defibrotide

ABSTRACT

Veno-occlusive disease (VOD) of the liver remains one of the most feared complications associated with high-dose chemotherapy and hematopoietic stem cell transplantation (SCT). As a clinical syndrome characterized by fluid retention, hyperbilirubinemia, and painful hepatomegaly, VOD incidence varies widely, but it is universally recognized that severe cases of VOD have an extremely poor prognosis, with mortality at day 100 after SCT in excess of 80%. Systemic anticoagulant and thrombolytic therapies have been tested extensively in this disease, but are largely ineffective and are associated with significant bleeding complications. In recent years, defibrotide (DF; a polydisperse oligonucleotide derived from porcine intestinal mucosa with antithrombotic and protective properties on the microvasculature but minimal hemorrhagic risk) has emerged as a promising therapy for VOD. In large, multicenter, international phase I/II trials targeting patients with severe VOD, DF has been associated with complete response rates between 36 and 60%, survival past transplant day 100 in the range of 32 to 50%, and few significant attributable side effects. On the basis of these encouraging results, a pivotal, prospective, multinational, phase III trial of DF is underway in patients with severe VOD, and should provide validation of this agent as a therapy for established disease with a high risk of mortality. This article reviews our current understanding of hepatic VOD after SCT and provides a summary of the data to date on the use of DF as both therapy and prophylaxis for this disease.

KEYWORDS

veno-occlusive disease (VOD) - sinusoidal obstruction syndrome - defibrotide - stem cell transplantation - bone marrow transplantation

REFERENCES

• 1 Bearman S I, Appelbaum F R, Buckner C D et al.. Regimen-related toxicity in patients undergoing bone marrow transplantation.  J Clin Oncol. 1988;  6(10) 1562-1568
• 2 Lee J L, Gooley T, Bensinger W, Schiffman K, McDonald G B. Venoocclusive disease of the liver after high-dose chemotherapy with alkylating agents: incidence, outcome and risk factors.  Hepatology. 1997;  26 149A
• 3 McDonald G B, Hinds M S, Fisher L D et al.. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients.  Ann Intern Med. 1993;  118 255-267
• 4 Carreras E, Bertz H, Arcese W et al.. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party.  Blood. 1998;  92(10) 3599-3604
• 5 Lee J L, Gooley T, Bensinger W, Schiffman K, McDonald G B. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome.  Biol Blood Marrow Transplant. 1999;  5(5) 306-315
• 6 Reiss U, Cowan M, McMillan A, Horn B. Hepatic venooclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients.  J Pediatr Hematol Oncol. 2002;  24(9) 746-750
• 7 Cesaro S, Pillon M, Talenti E et al.. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.  Haematologica. 2005;  90(10) 1396-1404
• 8 Bearman S I. The syndrome of hepatic veno-occlusive disease after marrow transplantation.  Blood. 1995;  85 3005-3020
• 9 Pihusch R, Salat C, Schmidt E et al.. Hemostatic complications in bone marrow transplantation: a retrospective analysis of 447 patients.  Transplantation. 2002;  74(9) 1303-1309
• 10 Bearman S I, Anderson G L, Mori M, Hinds M S, Shulman H M, McDonald G B. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation.  J Clin Oncol. 1993;  11(9) 1729-1736
• 11 Richardson P, Bearman S I. Prevention and treatment of hepatic venocclusive disease after high-dose cytoreductive therapy.  Leuk Lymphoma. 1998;  31 267-277
• 12 Chopra R, Eaton J D, Grassi A et al.. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study.  Br J Haematol. 2000;  111(4) 1122-1129
• 13 Richardson P G, Murakami C, Jin Z et al.. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.  Blood. 2002;  100(13) 4337-4343
• 14 Corbacioglu S, Greil J, Peters C et al.. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention.  Bone Marrow Transplant. 2004;  33(2) 189-195
• 15 Chalandon Y, Roosnek E, Mermillod B et al.. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation.  Biol Blood Marrow Transplant. 2004;  10(5) 347-354
• 16 Corbacioglu S, Honig M, Lahr G et al.. Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide.  Bone Marrow Transplant. 2006;  38(8) 547-553
• 17 Shulman H M, Gown A M, Nugent D J. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules.  Am J Pathol. 1987;  127 549-558
• 18 Shulman H M, Fisher L B, Schoch H G, Kenne K W, McDonald G B. Venoocclusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms.  Hepatology. 1994;  19 1171-1180
• 19 Sato Y, Asada Y, Hara S et al.. Hepatic stellate cells (Ito cells) in veno-occlusive disease of the liver after allogeneic bone marrow transplantation.  Histopathology. 1999;  34(1) 66-70
• 20 Vannucchi A M, Rafanelli D, Longo G et al.. Early hemostatic alterations following bone marrow transplantation: a prospective study.  Haematologica. 1994;  79(6) 519-525
• 21 Park Y D, Yasui M, Yoshimoto T et al.. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation.  Bone Marrow Transplant. 1997;  19 915-920
• 22 Lee J H, Lee K H, Kim S et al.. Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study.  Bone Marrow Transplant. 1998;  22(9) 883-888
• 23 Villalon L, Avello A G, Cesar J et al.. Is veno-occlusive disease a specific syndrome or the exacerbation of physiopathologic hemostatic changes in hematopoietic stem cell transplantation (HSCT)?.  Thromb Res. 2000;  99(5) 439-446
• 24 Deleve L D. Dacarbazine toxicity in murine liver cells: a model of hepatic endothelial injury and glutathione defense.  J Pharmacol Exp Ther. 1994;  268(3) 1261-1270
• 25 DeLeve L, Shulman H M, McDonald G B. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease).  Semin Liver Dis. 2002;  22(1) 27-42
• 26 Kumar S, DeLeve L D, Kamath P S, Tefferi A. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation.  Mayo Clin Proc. 2003;  78(5) 589-598
• 27 DeLeve L D, Kaplowitz N. Selective susceptibility of hepatic endothelial cells to dacarbazine toxicity, a model for hepatic venoocclusive disease.  Hepatology. 1991;  14 161A
• 28 DeLeve L D. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation.  Hepatology. 1996;  24 830-837
• 29 Hassan M, Ljungman P, Ringden O et al.. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.  Bone Marrow Transplant. 2000;  25(9) 915-924
• 30 de Jonge M E, Huitema A D, Beijnen J H, Rodenhuis S. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy.  Br J Cancer. 2006;  94(9) 1226-1230
• 31 el Mouelhi M, Kauffman F C. Sublobular distribution of transferases and hydrolases associated with glucuronide, sulfate and glutathione conjugation in human liver.  Hepatology. 1986;  6(3) 450-456
• 32 Teicher B A, Crawford J M, Holden S A et al.. Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide.  Cancer. 1988;  62(7) 1275-1281
• 33 Copelan E A, Bechtel T P, Avalos B R et al.. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation.  Bone Marrow Transplant. 2001;  27(11) 1121-1124
• 34 Grochow L B, Jones R J, Brundrett R B et al.. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation.  Cancer Chemother Pharmacol. 1989;  25(1) 55-61
• 35 Hassan M, Oberg G, Bekassy A N et al.. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology.  Cancer Chemother Pharmacol. 1991;  28(2) 130-134
• 36 Schuler U, Schroer S, Kuhnle A et al.. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted?.  Bone Marrow Transplant. 1994;  14 759-765
• 37 Lee J H, Choi S J, Kim S E et al.. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation.  Ann Hematol. 2005;  84(5) 321-330
• 38 Clopes A, Sureda A, Sierra J et al.. Absence of veno-occlussive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantation with targeted busulfan dosage.  Eur J Haematol. 2006;  77(1) 1-6
• 39 McDonald G B, Slattery J T, Bouvier M E et al.. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation.  Blood. 2003;  101(5) 2043-2048
• 40 Salat C, Holler E, Reinhardt B et al.. Parameters of the fibrinolytic system in patients undergoing BMT: elevation of PAI-1 in veno-occlusive disease.  Bone Marrow Transplant. 1994;  14 747-750
• 41 Richardson P, Krishnan A, Wheeler C et al.. Elevation of PAI-1 levels in BMT-associated VOD and changes seen with the use of defibrotide.  Blood. 1996;  88(10) 45A
• 42 Richardson P, Hoppensteadt D, Elias A et al.. Elevation of tissue factor pathway inhibitor [TFPI], thrombomodulin [TM] and plasminogen activator inhibitor-1 [PAI-1] levels in stem cell transplant [SCT]-Associated veno-occlusive disease [VOD] and changes seen with the use of defibrotide.  Blood. 1997;  90(10) 219 (Abst)
• 43 Richardson P G, Hoppensteadt D, Elias A D et al.. Elevation of endothelial stress products and trends seen in patients with severe veno-occlusive disease treated with defibrotide.  Thromb Haemost. 1999;  3185(suppl) 628
• 44 Nurnberger W, Michelmann I, Burdach S, Gobel U. Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications.  Ann Hematol. 1998;  76(2) 61-65
• 45 Salat C, Holler E, Kolbe H J et al.. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplant.  Blood. 1997;  89(6) 2184-2188
• 46 Lee J H, Lee K H, Kim S et al.. Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide.  Br J Haematol. 2002;  118(4) 1087-1094
• 47 Richardson P, Krishnan A, Wheeler C et al.. The use of defibrotide (DF) in BMT-associated veno-occlusive disease (VOD) (Meeting abstract).  Proc Am Soc Clin Oncol. 1996;  15 A13
• 48 Pihusch V, Pihusch M, Penovici M, Kolb H J, Hiller E, Pihusch R. Transforming growth factor beta-1 released from platelets contributes to hypercoagulability in veno-occlusive disease following hematopoetic stem cell transplantation.  Thromb Res. 2005;  116(3) 233-240
• 49 Anscher M S, Peters W P, Reisenbichler H, Petros W P, Jirtle R L. Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer.  N Engl J Med. 1993;  328(22) 1592-1598
• 50 DeLeve L D, Wang X, Kanel G C et al.. Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome.  Hepatology. 2003;  38(4) 900-908
• 51 Kuroki I, Miyazaki T, Mizukami I, Matsumoto N, Matsumoto I. Effect of sodium nitroprusside on ischemia-reperfusion injuries of the rat liver.  Hepatogastroenterology. 2004;  51(59) 1404-1407
• 52 Smith L H, Dixon J D, Stringham J R et al.. Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis.  Blood. 2006;  107(1) 132-134
• 53 Scrobohaci M L, Drouet L, Monem-Mansi A et al.. Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers.  Thromb Res. 1991;  63 509-519
• 54 Ferra C, de Sanjose S, Gallardo D et al.. IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation.  Haematologica. 1998;  83(12) 1082-1087
• 55 Eltumi M, Trivedi P, Hobbs J R et al.. Monitoring of veno-occlusive disease after bone marrow transplantation by serum aminopropeptide of type III procollagen.  Lancet. 1993;  342(8870) 518-521
• 56 Rio B, Bauduer F, Arrago J P, Zittoun R. N-terminal peptide of type III procollagen: a marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin.  Bone Marrow Transplant. 1993;  11(6) 471-472
• 57 Heikinheimo M, Halila R, Fasth A. Serum procollagen type III is an early and sensitive marker for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.  Blood. 1994;  83(10) 3036-3040
• 58 McDonald G B. Venocclusive disease of the liver following marrow transplantation.  Marrow Transplant Rev. 1993;  3(4) 49-56
• 59 Nevill T J, Barnett M J, Klingemann H G, Reece D E, Shepherd J D, Phillips G L. Regimen-related toxicity of a busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation.  J Clin Oncol. 1991;  9(7) 1224-1232
• 60 Matute-Bello G, McDonald G D, Hinds M S, Schoch H G, Crawford S W. Association of pulmonary function testing abnormalities and severe veno-occlusive disease of the liver after marrow transplantation.  Bone Marrow Transplant. 1998;  21(11) 1125-1130
• 61 Li C K, Shing M M, Chik K W et al.. Haematopoietic stem cell transplantation for thalassaemia major in Hong Kong: prognostic factors and outcome.  Bone Marrow Transplant. 2002;  29(2) 101-105
• 62 Armand P, Kim H, Cutler C et al.. Prognostic impact of elevated pre-transplant serum ferritin in patients undergoing myeloablative stem cell transplantation.  Blood. 2007; Jan 18;  , [epub ahead of print]
• 63 Blakolmer K, Jaskiewicz K, Dunsford H A, Robson S C. Hematopoietic stem cell markers are expressed by ductal plate and bile duct cells in developing human liver.  Hepatology. 1995;  21(6) 1510-1516
• 64 Gao Z, McAlister V C, Williams G M. Repopulation of liver endothelium by bone-marrow-derived cells.  Lancet. 2001;  357(9260) 932-933
• 65 Giles F J, Kantarjian H M, Kornblau S M et al.. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.  Cancer. 2001;  92(2) 406-413
• 66 McDonald G B. Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzmab ozogamicin (mylotarg (r)).  Clin Lymphoma. 2002;  2(suppl 1) S35-S39
• 67 Wadleigh M, Richardson P G, Zahrieh D et al.. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.  Blood. 2003;  102 1578-1582
• 68 Arceci R J, Sande J, Lange B et al.. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33 + acute myeloid leukemia.  Blood. 2005;  106(4) 1183-1188
• 69 McKoy J M, Angelotta C, Bennett C L et al.. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.  Leuk Res. 2007;  31 599-604
• 70 Rajvanshi P, Shulman H M, Sievers E L, McDonald G B. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy.  Blood. 2002;  99(7) 2310-2314
• 71 Ringden O, Ruutu T, Remberger M. al. e. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group.  Blood. 1994;  83(9) 2723-2730
• 72 Rozman C, Carreras E, Qian C et al.. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia.  Bone Marrow Transplant. 1996;  17 75-80
• 73 Styler M J, Crilley P, Biggs J. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis.  Bone Marrow Transplant. 1996;  18 171-176
• 74 Tran H, Petropoulos D, Worth L et al.. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.  Biol Blood Marrow Transplant. 2004;  10(11) 805-812
• 75 Soiffer R J, Dear K, Rabinowe S N et al.. Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation.  Transplantation. 1991;  52(6) 1014-1019
• 76 Moscardo F, Sanz G F, de La Rubia J et al.. Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34( + ) positive selection.  Bone Marrow Transplant. 2001;  27(9) 983-988
• 77 Moscardo F, Urbano-Ispizua A, Sanz G F et al.. Positive selection for CD34 + reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation.  Exp Hematol. 2003;  31(6) 545-550
• 78 Mori T, Shimizu T, Yamazaki R, Nakazato T, Ikeda Y, Okamoto S. Altered metabolism of tacrolimus in hepatic veno-occlusive disease.  Transpl Int. 2005;  18(10) 1215-1217
• 79 Antin J H, Kim H T, Cutler C et al.. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation.  Blood. 2003;  102 1601-1605
• 80 Cutler C, Henry N L, Magee C et al.. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.  Biol Blood Marrow Transplant. 2005;  11(7) 551-557
• 81 Fisher D C, Vredenburgh J J, Petros W P et al.. Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver.  Bone Marrow Transplant. 1998;  21(2) 117-122
• 82 Korbling M, Katz R L, Khanna A et al.. Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells.  N Engl J Med. 2002;  346(10) 738-746
• 83 Strauer B E, Brehm M, Zeus T et al.. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans.  Circulation. 2002;  106(15) 1913-1918
• 84 Hagglund H, Remberger M, Klaesson S, Lonnqvist B, Ljungman P, Ringden O. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation.  Blood. 1998;  92(12) 4568-4572
• 85 Jones R J, Lee K SK, Beschorner W E et al.. Venoocclusive disease of the liver following bone marrow transplantation.  Transplantation. 1987;  44 778-783
• 86 Brown B P, Abu-Yousef M, Farner R, LaBrecque D, Gingrich R. Doppler sonography: a noninvasive method for evaluation of hepatic venocclusive disease.  AJR Am J Roentgenol. 1990;  154 721-724
• 87 Lassau N, Auperin A, Leclere J, Bennaceur A, Valteau-Couanet D, Hartmann O. Prognostic value of doppler-ultrasonography in hepatic veno-occlusive disease.  Transplantation. 2002;  74(1) 60-66
• 88 Carreras E, Granena A, Navasa M et al.. Transjugular liver biopsy in BMT.  Bone Marrow Transplant. 1993;  11(1) 21-26
• 89 Shulman H M, Gooley T, Dudley M D et al.. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients.  Transplantation. 1995;  59 1015-1022
• 90 Pihusch M, Wegner H, Goehring P et al.. Diagnosis of hepatic veno-occlusive disease by plasminogen activator inhibitor-1 plasma antigen levels: a prospective analysis in 350 allogeneic hematopoietic stem cell recipients.  Transplantation. 2005;  80(10) 1376-1382
• 91 Barrett J, Childs R. Non-myeloablative stem cell transplants.  Br J Haematol. 2000;  111(1) 6-17
• 92 Tse W T, Beyer W, Pendleton J D, Richardson P, Guinan E C. Genetic polymorphisms in glutathione s-transferase and plasminogen activator inhibitor and risk of veno-occlusive disease (VOD).  Blood. 2000;  96 390A
• 93 Poonkuzhali S, Vidya S, Shaji R V, Chandy M, Srivastava A. Glutathione S-transferase gene polymorphism and risk of major undergoing allogeneic bone marrow transplantation.  Blood. 2001;  98(11) 852A
• 94 Haire W D, Cavet J, Pavletic S Z, Tarantolo S R, Norden J, Middleton P G. Tumor necrosis factor d3 allele predicts for organ dysfunction after allogeneic blood stem cell transplantation (ABSCT).  Blood. 2000;  96 584A
• 95 Hassan Z, Hellstrom-Lindberg E, Alsadi S, Edgren M, Hagglund H, Hassan M. The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo.  Bone Marrow Transplant. 2002;  30(3) 141-147
• 96 Sjoo F, Aschan J, Barkholt L, Hassan Z, Ringden O, Hassan M. N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation.  Bone Marrow Transplant. 2003;  32(4) 349-354
• 97 Ohashi K, Tanabe J, Watanabe R et al.. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation.  Am J Hematol. 2000;  64(1) 32-38
• 98 Essell J H, Thompson J M, Harman G S et al.. Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients.  Bone Marrow Transplant. 1992;  10(4) 367-372
• 99 Essell J H, Schroeder M T, Harman G S et al.. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial.  Ann Intern Med. 1998;  128(12 pt 1) 975-981
• 100 Ruutu T, Eriksson B, Remes K et al.. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation.  Blood. 2002;  100(6) 1977-1983
• 101 Attal M, Huguet F, Rubie H et al.. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial.  Blood. 1992;  79(11) 2834-2840
• 102 Bearman S I, Hinds M S, Wolford J L et al.. A pilot study of continuous infusion heparin for the prevention of hepatic veno-occlusive disease after bone marrow transplantation.  Bone Marrow Transplant. 1990;  5(6) 407-411
• 103 Marsa-Vila L, Gorin N C, Laporte J P et al.. Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation.  Eur J Haematol. 1991;  47(5) 346-354
• 104 Marsa-Vila L, Gorin N C, Laporte J P. Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation.  Eur J Haematol. 1991;  47 346-352
• 105 Or R, Nagler A, Shpilberg O et al.. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients.  Transplantation. 1996;  61(7) 1067-1071
• 106 Simon M, Hahn T, Ford L A et al.. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin.  Bone Marrow Transplant. 2001;  27(6) 627-633
• 107 Park S H, Lee M H, Lee H et al.. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation.  Bone Marrow Transplant. 2002;  29(2) 137-143
• 108 Forrest D L, Thompson K, Dorcas V G, Couban S H, Pierce R. Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study.  Bone Marrow Transplant. 2003;  31(12) 1143-1149
• 109 Forrest D L, Thompson K, Dorcas V G, Couban S H, Pierce R. Low molecular weight heparin for the prevention of veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study.  Bone Marrow Transplant. 2003;  31(12) 1143-1149
• 110 Lee J H, Lee K H, Choi J S et al.. Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment.  J Korean Med Sci. 1996;  11(2) 118-126
• 111 Gluckman E, Jolivet I, Scrobohaci M L et al.. Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation.  Br J Haematol. 1990;  74 277-281
• 112 Bearman S I, Shen D D, Hinds M S, Hill H A, McDonald G B. A phase I/II study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation.  Br J Haematol. 1993;  84 724-730
• 113 Versluys B, Bhattacharaya R, Steward C, Cornish J, Oakhill A, Goulden N. Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure.  Blood. 2004;  103(5) 1968 , (letter to editor)
• 114 Bearman S I, Lee J L, Baron A E, McDonald G B. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients.  Blood. 1997;  89(5) 1501-1506
• 115 Morris J D, Harris R E, Hashmi R et al.. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation.  Bone Marrow Transplant. 1997;  20(10) 871-878
• 116 Mertens R, Brost H, Granzen B, Nowak-Gottl U. Antithrombin treatment of severe hepatic veno-occlusive disease in children with cancer.  Eur J Pediatr. 1999;  158(suppl 3) S154-S158
• 117 Ibrahim R B, Peres E, Dansey R, Abidi M H, Abella E M, Klein J. Anti-thrombin III in the management of hematopoietic stem-cell transplantation-associated toxicity.  Ann Pharmacother. 2004;  38(6) 1053-1059
• 118 Haussmann U, Fischer J, Eber S, Scherer F, Seger R, Gungor T. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy.  Haematologica. 2006;  91(6) 795-800
• 119 Vaughan D E, Plavin S R, Schafer A I, Loscalzo J. PGE1 accelerates thrombolysis by tissue plasminogen activator.  Blood. 1989;  73(5) 1213-1217
• 120 Schlegel P G, Haber H P, Beck J et al.. Hepatic veno-occlusive disease in pediatric stem cell recipients: successful treatment with continuous infusion of prostaglandin E1 and low-dose heparin.  Ann Hematol. 1998;  76(1) 37-41
• 121 Eissner G, Multhoff G, Gerbitz A et al.. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide.  Blood. 2002;  100(1) 334-340
• 122 Bianchi G, Barone D, Lanzarotti E et al.. Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist.  Eur J Pharmacol. 1993;  238 327-334
• 123 Bracht F, Schror K. Isolation and identification of aptamers from defibrotide that act as thrombin antagonists in vitro.  Biochem Biophys Res Commun. 1994;  200(2) 933-936
• 124 Coccheri S, Biagi G, Legnani C, Bianchini B, Grauso F. Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man.  Eur J Clin Pharmacol. 1988;  35 151-156
• 125 Berti F, Rossoni G, Biasi G, Buschi A, Mandelli V. Defibrotide by enhancing prostacyclin generation prevents endothelin-I induced contraction in human saphenous veins.  Prostaglandins. 1990;  40 337-350
• 126 Zhou Q, Chu X, Ruan C. Defibrotide stimulates expression of thrombomodulin in human endothelial cells.  Thromb Haemost. 1994;  71 507-510
• 127 Fareed J. Modulation of endothelium by heparin and related polyelectrolytes. In: Nicolaides A, Novo S Advances in Vascular Pathology 1997. Amsterdam: Elsevier Science 1997
• 128 Ulutin O N. Antithrombotic effect and clinical potential of defibrotide.  Semin Thromb Hemost. 1993;  19 186-191
• 129 Jamieson A, Alcock P, Wood L, Tuffin D P. Effect of deoxyribonucleic acid derivative defibrotide on plasma fibrinolytic activity in the rat.  Br J Pharmacol. 1996;  106(suppl) 89P (abst)
• 130 Falanga A, Marchetti M, Vignoli A, Barbui T. Defibrotide (DF) modulates tissue factor expression by microvascular endothelial cells.  Blood. 1999;  94(10) 146A
• 131 Falanga A, Marchetti M, Vignoli A, Barbui T. Impact of defibrotide on the fibrinolytic and procoagulant properties of endothelial cell macro- and micro-vessels.  Blood. 2000;  96(11) 53 (abst)
• 132 Bonomini V, Frasca G M, Raimondi C, D'arcangelo G L, Vangelista A. Effect of a new antithrombotic agent (Defibrotide) in acute renal failure due to thrombotic microangiopathy.  Nephron. 1985;  40 195-200
• 133 Coccheri S, Biagi G. Defibrotide.  Cardiovasc Drug Rev. 1991;  9 172-196
• 134 Violi F, Marubini E, Coccheri S, Nenci G. Improvement of walking distance by defibrotide in patients with intermittent claudication-results of a randomized, placebo-controlled study (the DICLIS study). Defibrotide Intermittent CLaudication Italian Study.  Thromb Haemost. 2000;  83(5) 672-677
• 135 Richardson P G, Elias A D, Krishnan A et al.. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population.  Blood. 1998;  92(3) 737-744
• 136 Vangelista A, Frasca G M, Raimondi C, Liviano-D'Arcangelo G, Bonomini V. Effects of defibrotide in acute renal failure due to thrombotic microangiopathy.  Haemostasis. 1986;  16(suppl 1) 51-54
• 137 Richardson P, Soiffer R, Antin J H et al.. Defibrotide (Df) for the treatment of severe veno-occlusive disease (VOD) and multi-organ failure (MOF) post SCT: final results of a phase ii, multicenter, randomized study and preliminary analyses of surrogate markers and ultrasoud findins.  Blood. 2004;  104 , 350(abst)
• 138 Richardson P, Soiffer R, Antin J H et al.. Defibrotide (Df) for the treatment of severe veno-occlusive disease (VOD) and multi-organ failure (MOF) post SCT: final results of a phase ii, multi-center, randomized, does-finding trial.  Blood. 2006;  108 , 43(abst)
• 139 Bulley S R, Strahm B, Doyle J, Dupuis L L. Defibrotide for the treatment of hepatic veno-occlusive disease in children.  Pediatr Blood Cancer. 2006;  48 700-704
• 140 Schlitt H J, Tischler H J, Ringe B et al.. Allogeneic liver transplantation for hepatic veno-occlusive disease after bone marrow transplantation-clinical and immunological considerations.  Bone Marrow Transplant. 1995;  16 473-478
• 141 Smith F O, Johnson M S, Scherer LR, et al.. Transjugular intrahepatic portosystemic shunting (TPS) for the treatment of severe hepatic veno-occlusive disease.  Bone Marrow Transplant. 1996;  18 643-646
• 142 Alvarez R, Banares R, Casariego J et al.. Percutaneous intrahepatic portosystemic shunting in the treatment of veno-occlusive disease of the liver after bone marrow transplantation.  Gastroenterol Hepatol. 2000;  23(4) 177-180
• 143 Tefferi A, Kumar S, Wolf R C et al.. Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation.  Bone Marrow Transplant. 2001;  28(10) 997-999
• 144 Baglin T P, Harper P, Marcus R E. Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator (rt-PA).  Bone Marrow Transplant. 1990;  5(6) 439-441
• 145 Laporte J P, Lesage S, Tilleul P, Najman A, Gorin N C. Alteplase for hepatic veno-occlusive disease complicating bone-marrow transplantation.  Lancet. 1992;  339(8800) 1057
• 146 Rosti G, Bandini G, Belardinelli A et al.. Alteplase for hepatic veno-occlusive disease after bone-marrow transplantation.  Lancet. 1992;  339(8807) 1481-1482
• 147 Ringden O, Wennberg L, Ericzon B G et al.. Alteplase for hepatic veno-occlusive disease after bone marrow transplantation.  Lancet. 1992;  340(8818) 546-547
• 148 Leahey A M, Bunin N J. Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients.  Bone Marrow Transplant. 1996;  17 1101-1104
• 149 Feldman L, Gabai E, Milovic V, Jaimovich G. Recombinant tissue plasminogen activator (rTPA) for hepatic veno-occlusive disease after allogeneic BMT in a pediatric patient.  Bone Marrow Transplant. 1995;  16 727
• 150 Goldberg S L, Shubert J, Rao A K, Redei I, Klumpp T R, Mangan K F. Treatment of hepatic veno-occlusive disease with low-dose tissue plasminogen activator: impact on coagulation profile.  Bone Marrow Transplant. 1996;  18(3) 633-636
• 151 Higashigawa M, Watanabe M, Nishihara H et al.. Successful treatment of an infant with veno-occlusive disease developed after allogeneic bone marrow transplantation by tissue plasminogen activator, heparin and prostaglandin E1.  Leuk Res. 1995;  19 477-480
• 152 Hagglund H, Ringden O, Ljungman P. No beneficial effects, but severe side effects caused by recombinant human tissue plasminogen activator for treatment of hepatic veno-occlusive disease after allogeneic bone marrow transplantation.  Transplant Proc. 1995;  27 3535
• 153 Yu L C, Malkani I, Regueira O, Ode D L, Warrier R P. Recombinant tissue plasminogen activator (rt-PA) for veno-occlusive liver disease in pediatric autologous bone marrow transplant patients.  Am J Hematol. 1994;  46(3) 194-198
• 154 Schriber J, Milk B, Shaw D et al.. Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation.  Bone Marrow Transplant. 1999;  24(12) 1311-1314
• 155 Kulkarni S, Rodriguez M, Lafuente A et al.. Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD).  Bone Marrow Transplant. 1999;  23(8) 803-807
• 156 Richardson P G, Murakami C, Jin Z et al.. Multi-institutional use of defibrotide in 88 patients post stem cell transplant with severe veno-occlusive disease and multi-system organ failure; response without significant toxicity in a high risk population and factors predictive of outcome.  Blood. 2002;  100(13) 4337-4343